Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2020 1
2021 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for ml min m. hamal
Your search for Ma’mon M. Hatmal retrieved no results
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061371 Free PMC article. Clinical Trial.
Prespecified subgroups of eGFR included 2282 (34.5%) participants with an eGFR of less than 30 mL/min per 1.73 m(2), 2928 (44.3%) with an eGFR of 30 to less than 45 mL/min per 1.73 m(2), and 1399 (21.2%) with an eGFR 45 mL/min per 1.73 m( …
Prespecified subgroups of eGFR included 2282 (34.5%) participants with an eGFR of less than 30 mL/min per 1.73 m(2), 2928 (44. …
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061372 Free article. Clinical Trial.
Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1.73 m(2), or 45 to less than 90 mL/min per 1.73 m(2) with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. .. …
Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1.73 m(2), or 45 …
Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial.
Birudaraju D, Cherukuri L, Kinninger A, Dahal S, Lakshmanan S, Rezvanizadeh V, Ghanem AK, Flores F, Hamal S, Pozon RG, Adudodla N, Tayek JA, Roy SK, Budoff MJ. Birudaraju D, et al. J Diabetes Complications. 2021 Mar;35(3):107840. doi: 10.1016/j.jdiacomp.2020.107840. Epub 2020 Dec 31. J Diabetes Complications. 2021. PMID: 33419635 Clinical Trial.
Of interest, 14 persons with diabetes with normal coronaries (no calcification) were significantly more likely to be females (21% vs 62%), have higher glomerular filtration rate (106.5 19.4 vs 89.9 22.6 mL/min/1.73m(2); p= 0.006), and younger (53.4 9.0 vs 56.4 8.4 yrs.; p= …
Of interest, 14 persons with diabetes with normal coronaries (no calcification) were significantly more likely to be females (21% vs 62%), h …
Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer.
Chaftari AM, Hachem R, Jordan M, Garoge K, Al Hamal Z, El Zakhem A, Viola GM, Granwehr B, Mulanovich V, Gagel A, Reitzel R, Yousif A, Jiang Y, Raad I. Chaftari AM, et al. Antimicrob Agents Chemother. 2015 Oct 19;60(1):239-44. doi: 10.1128/AAC.00617-15. Print 2016 Jan. Antimicrob Agents Chemother. 2015. PMID: 26482312 Free PMC article. Clinical Trial.
Patients with baseline creatinine clearance (CLCR) values of >50 ml/min received 10 mg/kg/day of telavancin, and those with CLCR values between 30 and 49 ml/min received 7.5 mg/kg/day. ...
Patients with baseline creatinine clearance (CLCR) values of >50 ml/min received 10 mg/kg/day of telavancin, and those with CLCR v …